IBDEI0MR ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10226,2)
 ;;=^5002642
 ;;^UTILITY(U,$J,358.3,10227,0)
 ;;=I10.^^39^432^1
 ;;^UTILITY(U,$J,358.3,10227,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10227,1,3,0)
 ;;=3^Essential/Primary Hypertension
 ;;^UTILITY(U,$J,358.3,10227,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,10227,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,10228,0)
 ;;=I11.0^^39^432^12
 ;;^UTILITY(U,$J,358.3,10228,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10228,1,3,0)
 ;;=3^Hypertensive Heart Disease w/ Heart Failure
 ;;^UTILITY(U,$J,358.3,10228,1,4,0)
 ;;=4^I11.0
 ;;^UTILITY(U,$J,358.3,10228,2)
 ;;=^5007063
 ;;^UTILITY(U,$J,358.3,10229,0)
 ;;=I11.9^^39^432^13
 ;;^UTILITY(U,$J,358.3,10229,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10229,1,3,0)
 ;;=3^Hypertensive Heart Disease w/o Heart Failure
 ;;^UTILITY(U,$J,358.3,10229,1,4,0)
 ;;=4^I11.9
 ;;^UTILITY(U,$J,358.3,10229,2)
 ;;=^5007064
 ;;^UTILITY(U,$J,358.3,10230,0)
 ;;=I12.0^^39^432^5
 ;;^UTILITY(U,$J,358.3,10230,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10230,1,3,0)
 ;;=3^Hypertensive CKD w/ Stage 5 CKD or ESRD
 ;;^UTILITY(U,$J,358.3,10230,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,10230,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,10231,0)
 ;;=I12.9^^39^432^4
 ;;^UTILITY(U,$J,358.3,10231,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10231,1,3,0)
 ;;=3^Hypertensive CKD w/ Stage 1-4 CKD
 ;;^UTILITY(U,$J,358.3,10231,1,4,0)
 ;;=4^I12.9
 ;;^UTILITY(U,$J,358.3,10231,2)
 ;;=^5007066
 ;;^UTILITY(U,$J,358.3,10232,0)
 ;;=I13.0^^39^432^8
 ;;^UTILITY(U,$J,358.3,10232,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10232,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 1-4 CKD
 ;;^UTILITY(U,$J,358.3,10232,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,10232,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,10233,0)
 ;;=I13.10^^39^432^10
 ;;^UTILITY(U,$J,358.3,10233,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10233,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 1-4 CKD
 ;;^UTILITY(U,$J,358.3,10233,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,10233,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,10234,0)
 ;;=I13.11^^39^432^11
 ;;^UTILITY(U,$J,358.3,10234,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10234,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 5 CKD/ESRD
 ;;^UTILITY(U,$J,358.3,10234,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,10234,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,10235,0)
 ;;=I13.2^^39^432^9
 ;;^UTILITY(U,$J,358.3,10235,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10235,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 5 CKD/ESRD
 ;;^UTILITY(U,$J,358.3,10235,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,10235,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,10236,0)
 ;;=I15.0^^39^432^15
 ;;^UTILITY(U,$J,358.3,10236,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10236,1,3,0)
 ;;=3^Renovascular Hypertension
 ;;^UTILITY(U,$J,358.3,10236,1,4,0)
 ;;=4^I15.0
 ;;^UTILITY(U,$J,358.3,10236,2)
 ;;=^5007071
 ;;^UTILITY(U,$J,358.3,10237,0)
 ;;=I15.1^^39^432^3
 ;;^UTILITY(U,$J,358.3,10237,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10237,1,3,0)
 ;;=3^Hypertension Secondary to Oth Renal Disorders
 ;;^UTILITY(U,$J,358.3,10237,1,4,0)
 ;;=4^I15.1
 ;;^UTILITY(U,$J,358.3,10237,2)
 ;;=^5007072
 ;;^UTILITY(U,$J,358.3,10238,0)
 ;;=I15.2^^39^432^2
 ;;^UTILITY(U,$J,358.3,10238,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10238,1,3,0)
 ;;=3^Hypertension Secondary to Endocrine Disorders
 ;;^UTILITY(U,$J,358.3,10238,1,4,0)
 ;;=4^I15.2
